Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (14227)	7/26/2000 12:00:10 AM
From: Cacaito	Read Replies (1) \| Respond to of 17367

Blue, Windows 3.1 is more expensive than Windows 95 more than W98 and more than W2000, MSFT assures the transition via marketing pricing. Pharma do the same, they introduce the combo and keep it as the safe proven and FDA approved alternative, they killed the original, sometimes subtly like DNA plans to kill Growth Hormone1, GH2 is injected once a month, which parents are going to choose daily injections for their child even if generic? few, and in the third world, not the US. Same story Amgn killing their own daily Epogen (and J&J Procrit)with the new once a week NESP (and J&J has no right to the profits). Or a drastic killing, like J&J killing cisapride after 15 years of $billion dolar sale, now suddenly the arrythmias known all along are dangerous and concerned for patients they took out of the market (no generic possible, one arrythmia will bring a big lawsuit)but J&J will bring in two years (and for the next 17)r-cisapride the pure mirror image and no side effect Sepracor version. But, this is guessing to far, first rbpi21 must be proven to work. Well, Lilly could choose just to add it due to its safety just for the fun (patent extension) of it. No, just kitting around said the cat.